Table 1.
Summary of Studies Using Intraoperative Blood Salvage During Urologic Oncologic Surgery
| Study | Design | Cancer Type | Number of Patients (IOCS/No IOCS) | Follow-up | Outcome |
|---|---|---|---|---|---|
| Klimberg I et al27 | Retrospective cohort | RCC, urothelial, prostate | 13/0 24/0 10/0 | 12–23 mo | 2/13 developed pulmonary mets 2/24 had pelvic recurrence 1/10 had pelvic recurrence |
| Hart OJ 3rd et al28 | Retrospective cohort | Urothelial | 49/0 | 26 mo | 21% overall recurrence |
| Gray CL et al30 | Retrospective cohort | Prostate | 62/101 | 7 mo | Equivalent progression-free survival |
| Davis M et al31 | Retrospective cohort | Prostate | 87/321 | 40 mo | Equivalent rates of biochemical recurrence |
| Nieder AM et al32 | Retrospective cohort | Prostate | 265/773 | 40 mo | Equivalent rate of biochemical recurrence; same for low-, intermediate-, and high-risk disease |
| Raval JS et al33 | Retrospective cohort | Prostate | 42/32 | Minimum 5 years | Lower rates of biochemical recurrence and metastatic disease in IOCS group |
| Nieder AM et al34 | Retrospective cohort | Urothelial | 65/313 | 19 mo | Equivalent disease-specific survival |
| Aning J et al35 | Retrospective cohort | Urothelial | 194/19 | 24 mo | 3- and 5-y survival 58% and 49%; no comparison between groups |
| Lyon TD et al41 | Retrospective cohort | RCC | 33/36 | 23 mo | No cases of metastasis, 1 recurrence in non-IOCS group |
IOCS, intraoperative cell salvage; RCC, renal cell carcinoma.